Rituxan Problems?
Posted: Tue Dec 19, 2006 6:08 am
Just saw this article from Reuters re: PML showing up in a couple of Rituxan patients. Although the drug has been used for about 8 years with supposedly good safety results, one has to wonder why PML has decided to all of a sudden show up. I would hope that those MS patients involved in clinical trials with Rituxan will be closely monitored.
Harry
_______________________________
WASHINGTON (Reuters) - Two lupus patients died from a rare brain infection after taking the Genentech and Biogen Idec drug Rituxan, U.S. health officials said in an advisory issued on Monday.
Rituxan, authorized for lymphoma and rheumatoid arthritis, is not approved for treating lupus but doctors sometimes prescribe it for that use, the U.S. Food and Drug Administration said in a notice posted on its Web site.
Both patients died from a brain infection called progressive multifocal leukoencephalopathy, or PML, the FDA said. The agency urged doctors to discuss the chances of PML with Rituxan patients, saying there is no known treatment.
Rituxan's prescribing instructions already include information about reports of several types of viral infections, including PML, that became active again or worsened in cancer patients taking Rituxan.
"FDA is working to gather more information about Rituxan and PML and to strengthen the warnings about PML in the Rituxan product label," the agency said.
Biogen said it and Genentech issued a letter to doctors about the patients with lupus, an autoimmune disease.
Genentech spokeswoman Debra Charlesworth said clinical trials of Rituxan were ongoing for lupus and other conditions. The two lupus patients who died were not enrolled in a clinical trial, she said
Harry
_______________________________
WASHINGTON (Reuters) - Two lupus patients died from a rare brain infection after taking the Genentech and Biogen Idec drug Rituxan, U.S. health officials said in an advisory issued on Monday.
Rituxan, authorized for lymphoma and rheumatoid arthritis, is not approved for treating lupus but doctors sometimes prescribe it for that use, the U.S. Food and Drug Administration said in a notice posted on its Web site.
Both patients died from a brain infection called progressive multifocal leukoencephalopathy, or PML, the FDA said. The agency urged doctors to discuss the chances of PML with Rituxan patients, saying there is no known treatment.
Rituxan's prescribing instructions already include information about reports of several types of viral infections, including PML, that became active again or worsened in cancer patients taking Rituxan.
"FDA is working to gather more information about Rituxan and PML and to strengthen the warnings about PML in the Rituxan product label," the agency said.
Biogen said it and Genentech issued a letter to doctors about the patients with lupus, an autoimmune disease.
Genentech spokeswoman Debra Charlesworth said clinical trials of Rituxan were ongoing for lupus and other conditions. The two lupus patients who died were not enrolled in a clinical trial, she said